Expand CRSP Menu
CRSP MENU

CRSP Stock Summary and Trading Ideas (Crispr Therapeutics Ag - Common Shares | NASDAQ:CRSP)

Charts for Today's Stock Price and Implied Volatility in Crispr Therapeutics Ag - Common Shares

19-Dec-2025

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for CRSP by Theoretical Edge and Win Rates

Sentiment

News

Trading Statistics

Key Ratios

Crispr Therapeutics Ag - Common Shares (CRSP) Frequently Asked Questions

What does Crispr Therapeutics Ag - Common Shares do?

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

What symbol and exchange does Crispr Therapeutics Ag - Common Shares shares trade?

Crispr Therapeutics Ag - Common Shares trades on the NASDAQ stock market under the symbol CRSP.

What is Crispr Therapeutics Ag - Common Shares stock price doing today?

As of December 19, 2025, CRSP stock price climbed to $55.86 with 2,667,774 million shares trading.

What is Crispr Therapeutics Ag - Common Shares's Beta?

CRSP has a beta of 1.98, meaning it tends to be more sensitive to market movements. CRSP has a correlation of 0.30 to the broad based SPY ETF.

How much is Crispr Therapeutics Ag - Common Shares worth?

CRSP has a market cap of $5.32 billion. This is considered a Mid Cap stock.

How much money does Crispr Therapeutics Ag - Common Shares make?

Last quarter Crispr Therapeutics Ag - Common Shares reported $889,000 in Revenue and -$1.17 earnings per share. This fell short of revenue expectation by $-7 million and exceeded earnings estimates by $.13.

What is the highest and lowest price Crispr Therapeutics Ag - Common Shares traded in the last 3 year period?

In the last 3 years, CRSP traded as high as $91.10 and as low as $30.04.

What are the top ETFs holding Crispr Therapeutics Ag - Common Shares?

The top ETF exchange traded funds that CRSP belongs to (by Net Assets): ARKK, XBI, IWM, ARKG, VXF.

Is Crispr Therapeutics Ag - Common Shares (CRSP) a good investment?

CRSP has outperformed the market in the last year with a return of +36.0%, while the SPY ETF gained +17.3%. However, in the most recent history, CRSP shares have underperformed the stock market with its stock returning -11.2% in the last 3 month period and -4.0% for the last 2 week period, while SPY has returned +3.3% and -0.6%, respectively.

What are the support and resistance levels for Crispr Therapeutics Ag - Common Shares (CRSP)?

CRSP support price is $52.73 and resistance is $56.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRSP shares will trade within this expected range on the day.

Market Data Delayed 15 Minutes